Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Dr. Rathmell’s academic and clinical pedigree is as formidable as her administrative acumen. Before stepping into national prominence at the NCI, she distinguished herself at Vanderbilt University Medical Center, where she held the Hugh Jackson Morgan Endowed Professorship in Medicine and served as physician-in-chief and chair of the Department of Medicine. Her leadership at Vanderbilt championed integrated approaches combining clinical trials with translational research, particularly within the realm of kidney cancer.
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates.
A SETD2-CDK1-lamin axis maintains nuclear morphology and genome stability.
Targeted Metabolomic Methods for <sup>13</sup>C Stable Isotope Labeling with Uniformly Labeled Glucose and Glutamine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Vaccines in cancer treatment and prevention: the time is now.
Supplementary Protocol S1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Supplementary Figure S3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Figure 3 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Supplementary Figure S2 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Figure 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.
The All of Us Research Program is an opportunity to enhance the diversity of US biomedical research.
Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation.
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.
HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma.
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Using the National Cancer Plan to Drive Innovation in Cancer Research.
An orientation to the US National Cancer plan for the research community.
Clinical Trials-Real-World Data to Build a Future for Our Patients.
ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages.
PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.
Author Correction: Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.
Tumour atlases enable researchers to navigate through cancers.
Data from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)
From Improvised to Intentional: Re-Imagining the Physician-Scientist Career Path
Supplementary Table S4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i><i>-</i>Altered Advanced Solid Tumor Malignancies (NCI 10170)